(Q37640107)

21 August 2017

1 reference

title

Update on Rotarix: an oral human rotavirus vaccine (English)

1 reference

21 August 2017

1 reference

Miguel O'Ryan

1

1 reference

21 August 2017

Alexandre C Linhares

series ordinal

2

1 reference

21 August 2017

publication date

1 December 2009

1 reference

Expert Review of Vaccines

21 August 2017

published in

1 reference

21 August 2017

volume

8

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

1627-1641

1 reference

Global mortality associated with rotavirus disease among children in 2004.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Global Illness and Deaths Caused by Rotavirus Disease in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Rotavirus vaccines: targeting the developing world

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Rotavirus vaccine introduction in the Americas: progress and lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Rotavirus infection in Europe: time for effective prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Hospitalizations associated with rotavirus gastroenteritis in the United States, 1993-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Clinical presentations of rotavirus infection among hospitalized children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Rotavirus vaccination in Europe: the time has finally arrived

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Rotavirus vaccines: current prospects and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

The ever-changing landscape of rotavirus serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Mechanisms of protection against rotavirus infection and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Immunity and correlates of protection for rotavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Rotavirus infection in infants as protection against subsequent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Intussusception, rotavirus, and oral vaccines: summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

A critical review on a globally-licensed, live, orally-administrable, monovalent human rotavirus vaccine: Rotarix

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Rotarix (RIX4414): an oral human rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

The cost-effectiveness of rotavirus vaccination in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Rotavirus vaccine RIX4414 (Rotarix): a review of its use in the prevention of rotavirus gastroenteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Diarrhea- and Rotavirus-Associated Hospitalizations Among Children Less Than 5 Years of Age: United States, 1997 and 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Cost and cost-effectiveness of childhood vaccination against rotavirus in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

Cost-effectiveness and potential impact of rotavirus vaccination in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.136

21 January 2018

Identifiers

DOI

10.1586/ERV.09.136

1 reference

21 August 2017

1 reference